4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s phase I/II trial to assess its live biotherapeutic, MRx0518, in combination with immune checkpoint inhibitor Keytruda.
view4D pharma plc
4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial
Quick facts: 4D pharma plc
Price: 50.8363 GBX
LSE:DDDD
Market: LSE
Market Cap: £66.79 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
4D pharma: A clinical stage innovator and pioneer of Live Biotherapeutics
Most read
Mining
Money begins to flow towards the gold mining juniors in a big way, as a new...
5 days, 20 hours ago
Tech
Coronavirus: UK rolls out ‘game changer’ tests; govt mulls more bans; cruise...
22 hours, 57 minutes ago
Health
Tiziana Life Sciences makes patent application covering nasally-administered...
3 days, 22 hours ago
